Celgene Reiterates Commitment to Improving Pancreatic Cancer Care in Europe

With pancreatic cancer poised to become the third leading cause of cancer death in Europe, Celgene International Sàrl, a subsidiary of Celgene Corporation

, has today reiterated its commitment to patients and their families with the announcement that it will focus significant resources to increase awareness and understanding of the disease. Key initiatives include a clinical study programme involving more than 4,800 patients, as well as investment in research partnerships, both of which can help to uncover innovative new treatment options and advance the understanding of the biology of the disease. Celgene also is looking into opportunities to better understand the needs of patients and caregivers specifically, through dedicated research planned for later in 2014. These initiatives aim to help address the lack of progress in this disease, as highlighted by the Consumer Powerhouse European Pancreatic Cancer Index (EPCI) published on Tuesday.